Patent US4183932A successfully refreshed from Google Patents.
US4183932A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Fused quinazolinones and preparation thereof
Assignee: Sumitomo Chemical Co Ltd
•
Filing: 1978-01-31
•
Granted: 1980-01-15
•
Expires: 1998-01-31
Abstract
Abstract Tricyclic quinazolines of the formula, ##STR1## wherein R 1 , R 2 , R 3 , R 4 and A are as defined in the specification, such as 4,5-dihydro-5-arylimidazo[1,2-a]quinazolines, 4,5-dihydro-5-aryl-s-triazolo[4,3-a]quinazolines and 4,5-dihydro-5-aryltetrazolo[1,5-a]quinazolines having anti-inflammatory and analgesic activity are, for example, prepared by reducing the corresponding 4,5-unsaturated compounds, and then, if necessary, by alkylating the thus produced compounds.
Inventors
- 👤 Michihiro Yamamoto
- 👤 Masao Koshiba
- 👤 Hisao Yamamoto
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 17:33
CPC Classifications
C; C07; C07D; C07D487/00; C07D487/02; C07D487/04; A; A61; A61P; A61P29/00; C07D239/00; C07D239/70; C07D239/72; C07D239/78; C07D239/84
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
58 words
A compound of the formula, ##STR16## wherein R 1 , R 2 and R 3 are independently hydrogen, halogen, C 1-4 alkyl, C 1-4 alkoxy or nitro, and further R 1 and R 2 may together represent methylenedioxy; R 4 is hydrogen or C 1-4 alkyl; and A is N═N and a pharmaceutically acceptable acid addition salt thereof.
Claim 2
Dependent Claim
58 words
A compound of the formula, ##STR16## wherein R 1 , R 2 and R 3 are independently hydrogen, halogen, C 1-4 alkyl, C 1-4 alkoxy or nitro, and further R 1 and R 2 may together represent methylenedioxy; R 4 is hydrogen or C 1-4 alkyl; and A is N═N and a pharmaceutically acceptable acid addition salt thereof.
Claim 3
Dependent Claim
38 words
A compound according to claim 1, which is represented by the formula, ##STR17## wherein R 1 , R 2 , R 3 are as defined in claim 1, and R 4 ' is C 1 -C 4 alkyl.
Claim 4
Dependent Claim
38 words
A pharmaceutical composition containing as an active ingredient one or more compounds of the formula (I) or pharmaceutically acceptable acid addition salts thereof, which is given and defined in claim 1, and a pharmaceutically acceptable diluent or carrier.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1983-01-14 | 1983-07-16 | 1984-01-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1987-01-14 | 1987-07-16 | 1988-01-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1991-01-14 | 1991-07-16 | 1992-01-15 | $7700.00 | Window Closed / Lapsed |